homepage-top-section

Based in South San Francisco of California, Portola is engaged in the discovery, development and commercialisation of novel therapeutics for thrombosis and other haematologic conditions. The company’s commercialised

Junshi Biosciences, a Chinese biopharmaceutical company, is working to discover therapies to combat Covid-19 from the starting of the outbreak. The company has designed multiple neutralising antibodies and

The Government of Canada has granted the funds under Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) to support the discovery of antibodies for use in

The CAN-COVID study will assess the efficacy of using canakinumab for the treatment of a type of severe immune overreaction known as cytokine release syndrome (CRS) in people

The breakthrough therapy status will allow using of mobocertinib by patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has advanced on or after

The regulator has approved Sanofi’s biologics licence application (BLA) for MenQuadfi meningococcal (Groups A, C, Y, W) conjugate vaccine to prevent invasive meningococcal disease in persons aged two

Sponsored by Novartis, the trial will recruit around 440 patients to assess the efficacy of malaria drug to treat hospitalised patients with COVID-19 disease. Novartis’ generics and biosimilars

The regulator has approved Tukysa in combination with trastuzumab and capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who

The companies have signed a letter of intent to enter into collaboration for the development of a novel coronavirus vaccine by using their technologies. GSK CEO Emma Walmsley